A human abuse liability program for KP511
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs KP 511 (Primary)
- Indications Acute pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 28 Jun 2017 According to a KemPharm media release, the company anticipates initiating this program in the second half of 2017. Data expected in the second half of 2017.
- 14 Sep 2016 New trial record
- 10 Aug 2016 According to a KemPharm media release, the company anticipates initiating the KP511/ER human abuse liability program prior to the end of 2016.